MGX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $13,025,000.00

Insider Selling (Last 12 Months): $0.00

Metagenomi Insider Trading History Chart

Metagenomi Share Price & Price History

^$6.28

▲ +0.11 (1.78%)

As of 05/3/2024 03:59 PM ET

Days: 30 | 90 | 365

The AI Stock that’s Disrupting Every Industry

From StockEarnings | Ad

Move over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…

Here's the Ticker >>>

Metagenomi Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/13/2024	Holdings A/S Novo	Major Shareholder	Buy	800,000	$15.00	$12,000,000.00	1,739,175
2/9/2024	Holdings A/S Novo	Major Shareholder	Buy	100,000	$10.25	$1,025,000.00	100,000

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

SEC Filings (Institutional Ownership Changes) for Metagenomi (NASDAQ:MGX)

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Today's Range

Now: $6.28

$6.22

$6.69

50 Day Range

MA: $9.98

$6.17

$12.04

52 Week Range

Now: $6.28

$5.50

$12.74

Volume

52,816 shs

Average Volume

178,978 shs

Market Capitalization

$235.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Metagenomi?: Metagenomi's top insider shareholders include:
Holdings A/S Novo (Major Shareholder)
Learn More about top insider investors at Metagenomi.